Sanofi and PATH launch large-scale production of semi-synthetic artemisinin in Italy
French drug major Sanofi (Euronext: SAN) and non-profit global health organization PATH’s Drug Development program, established through an affiliation with OneWorld Health, yesterday (April 11) announced the launch of the large-scale production line of semi-synthetic artemisinin at Sanofi’s Garessio site in Italy.
Sanofi plans to produce 35 tons of artemisinin in 2013 and, on average, 50 to 60 tons per year by 2014 corresponding to around 80 to 150 million artemisinin-based combination therapies against malaria. The production of semi-synthetic artemisinin will be based on a no-profit, no-loss production model, in order to maintain a low price for the developing countries, the company states. There was no indication of the project's costs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze